{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T05:51:01Z","timestamp":1787032261901,"version":"build-2736575974"},"reference-count":0,"publisher":"The Medical Letter, Inc.","issue":"1727","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Med Lett Drugs Ther"],"abstract":"<jats:p>The FDA has approved diazoxide choline extended-release tablets (Vykat XR \u2013 Soleno Therapeutics) for treatment of hyperphagia in patients \u22654 years old with Prader-Willi syndrome. Diazoxide choline is the first drug to be approved in the US for this indication. Diazoxide oral suspension (Proglycem) has been available for years for management of symptomatic hypoglycemia.<\/jats:p>","DOI":"10.58347\/tml.2025.1727e","type":"journal-article","created":{"date-parts":[[2025,5,7]],"date-time":"2025-05-07T13:01:10Z","timestamp":1746622870000},"page":"e72-e73","source":"Crossref","is-referenced-by-count":3,"title":["Diazoxide Choline (Vykat XR) for Prader-Willi Syndrome-Associated Hyperphagia"],"prefix":"10.58347","volume":"67","author":[{"name":"Editors from The Medical Letter","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"37151","published-online":{"date-parts":[[2025,4,28]]},"container-title":["The Medical Letter on Drugs and Therapeutics"],"original-title":[],"deposited":{"date-parts":[[2025,5,7]],"date-time":"2025-05-07T13:01:11Z","timestamp":1746622871000},"score":1,"resource":{"primary":{"URL":"https:\/\/secure.medicalletter.org\/TML-article-1727e"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,28]]},"references-count":0,"journal-issue":{"issue":"1727","published-online":{"date-parts":[[2025,4,28]]}},"URL":"https:\/\/doi.org\/10.58347\/tml.2025.1727e","relation":{},"ISSN":["1523-2859"],"issn-type":[{"value":"1523-2859","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,28]]}}}